Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Expert Opinion on Radius' (RDUS) Market Potential for Recently Approved Osteoporosis Drug TYMLOS (abaloparatide)

Ticker(s): RDUS, AMGN, LLY

Who's the expert?

Name: Dr Theresa Guise - MD

Institution: Indiana University

  • Professor of Medicine and Jerry W. and Peg S. Throgmartin Professor of Oncology in the Department of Medicine, Division of Endocrinology at Indiana University.
  • Directs a metabolic bone disease clinic at IU where all of the patients have bone disease and a majority are postmenopausal women. Treats ~10-12 patients/week with injectable osteoporosis drugs (anti-resorptives denosumab and reclast or anabolics forteo or abaloparatide).
  • Clinical interests include diseases of calcium and bone metabolism, and has been the recipient of numerous grants for research on the skeletal health in cancer patients. Dr. Guise is a frequent lecturer and has been published in over 100 peer reviewed journals.

Interview Questions
Q1.

What is your medical background? How many patients do you treat with osteoporosis?

Added By: kcmckee
Q2.

What are your thoughts on current osteoporosis treatments? What is your typical approach to tackling the various types of osteoporosis patients you see?

Added By: kcmckee
Q3.

What are your thoughts on teriparatide vs abaloparatide? What benefits and concerns do you see for each?

Added By: kcmckee
Q4.

Do you think the osteosarcomas present in rats during testing of abaloparatide warrants serious concern? Do you prescribe abaloparatide? If not, what would it take for you to prescribe abaloparatide?

Added By: kcmckee
Q5.

What percentage of your osteoporosis patients would you consider eligible for abaloparatide? What is your ideal candidate for this drug?

Added By: kcmckee
Q6.

Do you think RDUS’ transdermal patch for abaloparatide will be approved? Do you envision a transdermal delivery method impacting efficacy?

Added By: kcmckee
Q7.

What are your thoughts on the recent rejection of AMGN’s osteoporosis drug? Could you see this receiving approval further down the road?

Added By: kcmckee
Q8.

What percent of the market do you see abaloparatide inhabiting relative to teriparatide? Do you think abaloparatide has the potential to expand into other markets (like men with osteoporosis)?

Added By: kcmckee

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.